EASL 2011: Kidney Function in HIV/HBV Coinfected People on Tenofovir
- Details
- Category: HIV/HBV Coinfection
- Published on Tuesday, 19 April 2011 09:34
- Written by Liz Highleyman
Impaired kidney function among people with HIV, HBV, and HIV/HBV coinfection taking tenofovir mainly occurred in those with pre-existing risk factors, researchers reported at EASL 2011. 
Boosted Danoprevir Improves Response in Prior Null Responders
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 19 April 2011 08:09
- Written by Liz Highleyman
Nearly 90% of genotype 1b prior non-responder hepatitis C patients treated with ritonavir-boosted danoprevir plus pegylated interferon/ribavirin experienced early virological response at week 12, but breakthrough reached 50% for those with genotype 1a. 
EASL 2011: Pegylated Interferon Lambda Boosts Response with Few Side Effects
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 15 April 2011 06:54
- Written by Bristol-Myers Squibb
Hepatitis C patients taking an experimental interferon formulation -- pegylated interferon lambda -- had higher rates of rapid and early virological response, with fewer flu-like symptoms and blood cell deficiencies, according to a report at EASL 2011.
EASL 2011: Monoclonal Antibody Bavituximab Well-Tolerated by HIV/HCV Coinfected People
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 15 April 2011 14:37
- Written by Peregrine
An experimental monoclonal antibody that inhibits HCV replication was safe and well-tolerated in a clinical trial of HIV positive people coinfected with chronic hepatitis C, researchers reported at EASL 2011.
EASL 2011: Once-Daily BI 201335 Ups Response to Interferon for Hepatitis C
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 15 April 2011 05:47
- Written by Liz Highleyman
Boerhinger Ingelheim's experimental HCV protease inhibitor BI 201335 added to pegylated interferon and ribavirin improved sustained response rates for both treatment-naive and treatment-experienced genotype 1 patients, researchers reported at EASL 2011. 
Web Design and Development by